Home » Topics » Deals and M&A » Collaboration

Collaboration
RSS

Cephalon and Alba Therapeutics enter option agreement for larazotide acetate

Feb. 11, 2011

European phase IIb study of Posidur meets primary endpoints

Feb. 10, 2011

Tacere Therapeutics reacquires Asian rights to RNAi-based agents targeting HCV

Feb. 10, 2011

Cepheid and FIND collaborate on Xpert HIV viral load test

Feb. 10, 2011

Circassia acquires worldwide rights to psoriasis and atopic dermatitis treatment PAP-1

Feb. 9, 2011

Biovail Labs acquires Canadian license for Aczone from Allergen

Feb. 9, 2011

Elan and Boehringer Ingelheim to codevelop antibody-based therapeutics

Feb. 9, 2011

Lundbeck is granted rights to several Cephalon products in Canada and Latin America

Feb. 8, 2011

Ansaris earns milestone payment from Ono Pharma with identification of kinase-related agent

Feb. 8, 2011

Optimer Pharma and Astellas enter agreement for antibiotic fidaxomicin

Feb. 8, 2011

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...